ABSTRACT
The management of atopic diseases has been revolutionised by precision therapies and biological drugs that target specific immune proteins. This report elucidates a unique complication from the use of the monoclonal antibody, dupilumab, that primary care providers and subspecialists need to be aware of. A patient in her 40s consulted us for severe atopic asthma, food allergy and eczema involving the face and body. She had previously failed treatments and was started on dupilumab (which binds to the interleukin-4 [IL4] receptor and inhibits both IL-4 and IL-13). She quickly achieved remission of asthma, rhinitis and eczema. Therapy was, however, complicated by severe blepharoconjunctivitis, dry eyes and periorbital dermatitis, consistent with dupilumab-induced ocular surface disease and dupilumab-associated mucin deficiency. Following aggressive treatment of ocular disease, the patient was able to continue dupilumab injections for asthma and eczema. It is presumed that dupilumab-induced cytokine imbalance results in ocular goblet cell dysfunction, mucin deficiency and ocular disease.
Subject(s)
Asthma , Dermatitis, Atopic , Dry Eye Syndromes , Eczema , Antibodies, Monoclonal, Humanized , Asthma/drug therapy , Dermatitis, Atopic/drug therapy , Eczema/chemically induced , Eczema/drug therapy , Female , Humans , Mucins , Severity of Illness Index , Treatment OutcomeABSTRACT
PURPOSE: To compare the results of 1-site versus 2-site combination glaucoma filtration and phacoemulsification surgery with respect to visual acuity, intraocular pressure (IOP), and glaucoma medication requirements via a case control study. METHODS: Results of 2-site phacotrabeculectomy surgery in 64 eyes of 59 patients were retrospectively reviewed with a minimum follow-up of 1 year. The 2-site procedures were compared with a randomly chosen control group of 71 1-site phacotrabeculectomies performed by the same surgeon. RESULTS: The presurgical visual acuity, IOP, and glaucoma medication requirements did not differ significantly between the 2 groups. Mean final postoperative results at 1 year for 2-site versus 1-site eyes, respectively, were visual acuity 0.32 +/- 0.353 (SD) and 0.32 +/- 0.37 (P = .99), IOP 15.0 +/- 3.7 mm Hg and 15.1 +/- 6.3 mm Hg (P = .97), and glaucoma medication requirements 0.43 +/- 0.90 and 0.61 +/- 1.1 (P = .52). CONCLUSION: There was no statistically significant difference in the final visual acuity, IOP, or glaucoma medication requirements between the 2-site and 1-site groups.
Subject(s)
Antihypertensive Agents/administration & dosage , Intraocular Pressure/physiology , Phacoemulsification/methods , Trabeculectomy/methods , Visual Acuity/physiology , Case-Control Studies , Cataract/complications , Cataract/therapy , Fluorouracil/administration & dosage , Follow-Up Studies , Glaucoma/complications , Glaucoma/surgery , Humans , Intraocular Pressure/drug effects , Intraoperative Complications , Lens Implantation, Intraocular/methods , Mitomycin/administration & dosage , Postoperative Complications , Prognosis , Retrospective Studies , Tonometry, OcularABSTRACT
Ki-1 (CD30) positive anaplastic large cell lymphoma (ALCL) is an uncommon, high-grade non-Hodgkin's lymphoma with distinct morphologic and immunohistochemical features. Solitary or multiple ulcerated nodules typically characterize cutaneous involvement. Erythroderma is very rare. We report the first case of primary nodal ALCL in which disease relapse manifested as generalized papules, nodules, and erythroderma. This unusual case expands the spectrum of cutaneous disease associated with Ki-1 positive ALCL and highlights the need for early biopsy in patients with a history of Ki-1 positive ALCL who have skin lesions develop.
Subject(s)
Dermatitis, Exfoliative/etiology , Ki-1 Antigen/metabolism , Lymphoma, Large-Cell, Anaplastic/complications , Neoplasm Recurrence, Local/metabolism , Skin Neoplasms/complications , Adult , Fatal Outcome , Humans , Immunohistochemistry , Lymphoma, Large-Cell, Anaplastic/metabolism , Male , Skin Neoplasms/metabolismABSTRACT
BACKGROUND: The occurrence of bullous lesions in localized or systemic scleroderma is rare. Three histologic patterns have been reported: lichen sclerosus et atrophicus-like, lymphangiectatic blisters and autoimmune blistering diseases. OBJECTIVE: To investigate the frequency, clinical, and immunopathologic features of patients with scleroderma and bullous eruptions and to review the literature regarding this rare condition. METHODS: A retrospective study of 53 cases of scleroderma (localized, generalized, and systemic) in the dermatology and rheumatology clinics at one institution over an 8-year span. Clinical, serologic, and immunopathologic findings were analyzed in four cases. RESULTS: Four of 53 patients exhibited bullous lesions in association with scleroderma. The first case illustrates lymphangioma-like clinical and pathologic presentation. The second case demonstrates bullous lichen sclerosus et atrophicus-like pattern. The other two cases exemplify a superimposed autoimmune skin disease, epidermolysis bullosa acquisita and penicillamine induced pemphigus foliaceus after treatment for systemic scleroderma. CONCLUSIONS: Of the 53 original patients, we have described four cases of bullous scleroderma (7.5%) Illustrating several pathogenetic mechanisms of bulla formation. inflammatory (lichen sclerosus et atrophicus), fibrotic/obstructive (lymphangiomatous), autoimmune (epidermolysis bullosa acquisita), and pemphigus foliaceus. The final case illustrates bullae as a complication of therapy for the underlying scleroderma.
